Innate Pharma (IPHA)
(Delayed Data from NSDQ)
$2.35 USD
-0.02 (-0.86%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $2.32 -0.03 (-1.28%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Brokerage Reports
Innate Pharma S.A. Sponsored ADR [IPHA]
Reports for Purchase
Showing records 1 - 20 ( 29 total )
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
MF Data Could Inform Regulatory Pathway for Lacutamab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Preclinical Data with Novel ADC Suggests Competitive Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Regulatory Pathway for Lacutamab Coming into Focus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Strong Data in SS Support Filing of BLA For Accelerated Approval of Lacutamab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Year-End Lacutamab Updates Under the Spotlight; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
TELLOMAK Final Readout in 2H23; ANKET-Based Programs Progressing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Tellomak Analyzed With New Lymph Node Evaluation Criteria Remains Positive; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Focus on Lacutamab Readouts in 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
TELLOMAK Final Readout in 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
TELLOMAK Readout at ASH; Continued Clinical Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
TELLOMAK Update Underscores Lacutamab''s Potential in MF; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Awaiting Pivotal Lacutamab Data 2H22; Pipeline Progressing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Monalizumab Achieved Another Milestone; TELLOMAK Readouts on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Pipeline Continues to Progress in 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Positive Clinical Update on Monalizumab at ESMO-IO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Durvalumab COAST Update Makes a Splash at ESMO
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Lacutamab Shows Promise in Mycosis Fungoides; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Initial Lacutamab MF Data Imminent; R&D Day in Mid-2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Executing Pipeline Advancement Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S